论文部分内容阅读
目的:了解2007～2008年成都地区17家医院生物制品及生化药品的使用状况。方法:采用限定日剂量(DDD)的方法,对成都地区2007～2008年17家医院生物制品及生化药品的销售金额、用药频度(DDDs)等进行统计分析。结果:2007年、2008年成都地区17家医院生物制品及生化药品销售总额分别为7338万元、9786万元;分别占总销售额的4.83%、5.00%。销售金额进入总销售额排名前100位的生物制品及生化药品有:人血白蛋白、胸腺肽、丙种球蛋白、促白细胞生长素和环磷腺苷。环磷腺苷在生物制品及生化药品中的DDDs最高。结论:生物制品及生化药品的价格及供给对其临床使用有较大的限制。
Objective: To understand the use status of biologic and biochemical drugs in 17 hospitals in Chengdu from 2007 to 2008. Methods: The DDD method was used to analyze the sales amount, frequency of DDDs, etc. of 17 hospitals’ biologics and biochemicals in Chengdu from 2007 to 2008. Results: In 2007 and 2008, the total sales of biological products and biochemical drugs in 17 hospitals in Chengdu were 73.38 million yuan and 97.86 million yuan respectively, accounting for 4.83% and 5.00% of the total sales respectively. Sales amount into the top 100 of total sales of biological products and biochemical drugs are: human serum albumin, thymosin, gamma globulin, leukocyte growth hormone and cyclic adenosine monophosphate. Cyclophosphamide in biological and biochemical drugs DDDs highest. Conclusion: The price and supply of biological products and biochemical drugs have great limitations on their clinical use.